Ad hoc announcement pursuant to Art. 53 LR André C. Muller, current CEO of Idorsia, to retire and act as an advisor to the company to ensure a smooth transition Allschwil, Switzerland - June 10 ...

For further information, please contact: Investor & Media Relations Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil +41 58 844 10 10 investor.relations@idorsia.com - media ...

Ad hoc announcement pursuant to Art. 53 LR André C. Muller, current CEO of Idorsia, to retire and act as an advisor to the ...

Swiss pharma company Idorsia (SIX: IDIA) today announced the appointment of Dr Srishti Gupta as chief executive (CEO), ...

The Fabry disease market is growing due to rising prevalence and better diagnostics. While ERTs and GALAFOLD dominate, emerging gene therapies and new treatments show promise. However, pediatric ...

Idorsia Pharmaceuticals has claimed FDA approval for aprocitentan as a treatment for resistant hypertension, becoming the first drug in the endothelin receptor antagonist class for that indication.

Amicus Therapeutics is growing steadily with Galafold and a promising Pompe therapy, targeting $1B revenue by 2028. See why ...

Significant reductions in proteinuria, estimated glomerular filtration rate stability of the C3/C3b inhibitor were also ...

Idorsia Ltd (SIX: IDIA) today announced the appointment of ... Dr. Gupta spent 18 years at McKinsey & Company as a senior leader in the pharmaceutical and global health practices. She has since served ...

Santhera Pharmaceuticals will launch its new drug ... The company licensed in a three-way deal with fellow Swiss firm Idorsia (formerly Actelion) and US biotech ReveraGen BioPharma shortly ...